Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to ...

If you are struggling to navigate the complexity of early commercialisation, rest assured, you are not alone. Clinical trial ...

Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to ...

Elevate your MedEd strategy with our 2025 toolkit! From AI-driven patient avatars to interactive augmented reality scenarios, ...

Novo Nordisk has announced an investment of 8.5 billion Danish kroner, or approximately $1.2bn, to establish a new rare ...

Gilead Sciences’ seladelpar has been recommended by the European Medicines Agency’s human medicines committee to treat the ...

Presenting your brand strategy for review by your most senior colleagues is a big deal, both professionally and personally.

Technology’s ability to accelerate the pace of innovation while reducing the cost is changing the dynamic of the struggle ...

As the awe of AI continues to dissipate, organisations are increasingly seeing this technology for its untapped promise to ...

Since the Orphan Drug Act was passed in 1983, pharmaceutical companies have increasingly focused on developing treatments for rare diseases. As a result, competition in the rare disease field is ...